3,022
Views
10
CrossRef citations to date
0
Altmetric
Biologics

Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore

, MScORCID Icon, , MPHORCID Icon, , MScORCID Icon, , MBBS, MRCPORCID Icon, , MBBS, MRCP, FAMSORCID Icon, , MPH & , MClinPharm, MPHORCID Icon show all
Pages 189-199 | Received 09 Jun 2020, Accepted 11 Oct 2020, Published online: 10 Nov 2020